Fenbendazole is a benzimide anthelmintic, used to treat parasitic worms including roundworms, hookworms, whipworms, lungworms and certain tapeworms. This medication has also been shown to help cancer patients when combined with other treatments.
The drug works by disrupting microtubules, which are vital to cell growth and division. It also boosts production of a gene called p53, which can kill cells that are abnormally growing and dividing.
Recently, interest in this compound has increased because of some fenbendazole cancer success stories, particularly of a man with stage 4 lung cancer who was given 3 months to live when he began taking the dewormer along with other supplements. The fenbendazole treatment protocol has been gaining popularity, but more research is needed to determine whether it will have a meaningful impact on human cancers.
To test if fenbendazole could be useful as a radiosensitizer in cancer therapy, EMT6 tumor-bearing mice were randomized to serve as untreated controls or to receive one of three treatments: 1) i.p. injections of fenbendazole at the times indicated by the dark arrows; 2) 10 Gy of x-rays alone; or 3) three daily i.p. injections of x-rays plus fenbendazole. After treatment, tumors were irradiated and the survival of irradiated cells was monitored.
Despite the chemical structure of fenbendazole resembling those of compounds known to act as radiosensitizers, our experiments showed that the drug had no effect on the radiation response of aerobic or hypoxic cultures. Furthermore, fenbendazole did not alter the tumor growth rate of unirradiated or irradiated cultures. fenbendazole 222mg capsules for humans